News Archive

Position Summary

GenVec is seeking a highly motivated professional who is able to make strong contributions in supporting all business and corporate development activities. The successful candidate will work directly with the Chief Executive Officer and will interact extensively with the scientific, legal, and financial personnel of the company to review and evaluate the scientific and commercial aspects of potential transactions. The Business Development Analyst will be responsible for supporting a portfolio of business development projects which address in-licensing, out-licensing, and acquisition opportunities for GenVec.

Roche has become the latest pharmaceutical company to join the connected health party at Qualcomm Life — in this case to do remote patient monitoring. The goal of the strategic collaboration is to generate big data insights on patients’ condition to reduce complications from chronic conditions, according to a company statement.

Vaccinations are obviously a hot topic for debate – it’s exhausting. But with the recent measles outbreak at Disneyland, it’s even more clear that this is getting just a bit ridiculous.

Parents really want to know who’s vaccinated and who’s not. And families in some states should be a little more concerned than others, according to numbers from the Centers for Disease Control.

Qiagen NV  (NASDAQ: QGEN  ) solutions are used every day by healthcare providers to analyze patient DNA and RNA in order to guide treatment and by researchers pursuing next generation medicine. The opportunity for Qiagen to help the industry deliver the right drug to the right patient at the right dose at the right time is big, but a significant drop-off in revenue from a legacy product meant that potential didn’t translate into significant sales growth last year.

Benjamin H. Wu has been named the new Deputy Secretary of the Maryland Department of Business and Economic Development, Governor Larry Hogan and DBED Secretary Mike Gill announced today.

A former DBED employee, Wu is among the first Cabinet deputies to be named to the Hogan administration. He will act as Chief Operating Officer, responsible for overseeing the Department’s charge of attracting companies to the State, as well as working with in-state companies to help them expand and add jobs, while connecting them to partners and resources.

LSN researchers recently decided to take a deep dive into interviews we have held with venture philanthropy groups from around the world to see what the future likely has in store. After analyzing data gathered over the past three years from more than 150 investors, we uncovered a few notable trends.

Every startup wants to change the world, but DC-based incubator and seed fund 1776 fosters the type of early stage companies that just might have a chance.

The incubator is focused specifically on startups for the public good and you won’t find any benign photo sharing apps in 1776’s portfolio.

MedImmune, the global biologics research and development arm of AstraZeneca, is probably best known for its work in discovering and developing therapeutics based on antibodies -protein molecules produced by the body as a primary immune response. However, for a number of reasons, including the large size of the molecule, antibodies may not always offer the most appropriate solution for treating some diseases. In those cases there may be alternative, innovative approaches which can be explored in parallel with our usual work with antibodies.

A U.S. House of Representatives panel today released a widely anticipated proposal for speeding the development of new medical treatments. The massive, 393-page document, dubbed the 21st Century Cures Act, has been under development by Fred Upton (R–MI) and Diana DeGette (D–CO) of the House Energy and Commerce Committee since last April. It grew out of a series of hearings and roundtables last year on ways to spur biomedical research innovation and streamline clinical trials and the drug approval process. The result is a long list of ideas summarized in this document.

The Federal Laboratory Consortium for Technology Transfer is proud to announce the winners of its 2015 Awards. Now in its 32nd year, the awards have recognized the outstanding efforts of scientists, technology transfer professionals, and their partners in academia and industry. Many technological breakthroughs that have become an essential part of our everyday lives have been winners of the FLC awards.

This year, nearly 100 nominations were submitted from eight federal agencies, which made the decision to select 23 winners a difficult one. But those selected represent technology transfer at its highest level.